ZYME has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZYME has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Zymeworks's Gross Profit for the three months ended in Mar. 2024 was $10.03 Mil. Zymeworks's Revenue for the three months ended in Mar. 2024 was $10.03 Mil. Therefore, Zymeworks's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.
The historical rank and industry rank for Zymeworks's Gross Margin % or its related term are showing as below:
Zymeworks had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Zymeworks was 0.00% per year.
The historical data trend for Zymeworks's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
Zymeworks Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Gross Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Zymeworks's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zymeworks's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Zymeworks's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Zymeworks's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as
Gross Margin % (A: Dec. 2023 ) | = | Gross Profit (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | 76 | / | 76.012 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (76.012 - 0) | / | 76.012 | |
= | N/A % |
Zymeworks's Gross Margin for the quarter that ended in Mar. 2024 is calculated as
Gross Margin % (Q: Mar. 2024 ) | = | Gross Profit (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | 10 | / | 10.03 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (10.03 - 0) | / | 10.03 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Zymeworks (NAS:ZYME) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Zymeworks had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Zymeworks's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Andrew Moore | officer: Chief Scientific Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Christopher Astle | officer: SVP & Chief Financial Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Kenneth Galbraith | director, officer: Chair & CEO | OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1 |
Carlos Campoy | director | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Miller Derek John Michael | director | 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709 |
Neil A Klompas | officer: President & COO | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Lota S. Zoth | director | 334 CR 692, BUFFALO GAP TX 79508 |
Troy Cox | director | C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141 |
Kenneth J. Hillan | director | C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080 |
Hollings Renton | director | |
Kelvin Neu | director | 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014 |
Natalie Sacks | director | C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710 |
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Neil Josephson | officer: Chief Medical Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
From GuruFocus
By Marketwired • 10-16-2023
By Marketwired • 08-10-2023
By GuruFocus Research GuruFocus Editor • 12-15-2022
By sperokesalga sperokesalga • 04-18-2023
By Business Wire Business Wire • 12-19-2022
By Business Wire Business Wire • 12-09-2022
By Business Wire Business Wire • 01-25-2023
By sperokesalga sperokesalga • 05-01-2023
By Marketwired • 08-01-2023
By Business Wire Business Wire • 11-29-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.